Crossmark

A protein-targeting strategy used to develop a selective inhibitor of the E17K point mutation in the PH domain of Akt1

Crossref DOI link: https://doi.org/10.1038/nchem.2223

Published Online: 2015-04-13

Published Print: 2015-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Deyle, Kaycie M.

Farrow, Blake https://orcid.org/0000-0002-1007-7111
Qiao Hee, Ying

Work, Jeremy

Wong, Michelle

Lai, Bert

Umeda, Aiko

Millward, Steven W.

Nag, Arundhati

Das, Samir

Heath, James R.
License Information

Text and Data Mining valid from 2015-04-13
More Information

Article History

Received: 17 September 2014

Accepted: 27 February 2015

First Online: 13 April 2015

Competing interests

: J.R.H. is a founder and board member of Indi Molecular. Indi Molecular is seeking to commercialize the PCC-agent technology. B.L. is an employee of Indi Molecular. K.M.D. has consulted for Indi Molecular. The patent ‘Multi-ligand capture agents and related compositions, methods and systems’ (Patent WO2009155420 A1) by H. Agnew <i>et al.</i> was published 23 December 2009.